NATIXIS PARTNERS ADVISED 21 INVEST AND ARDIAN ON THE SALE OF SYNERLAB TO BLUE WOLF CAPITAL

Founded in 2001 and based in Strasbourg, Synerlab is a major European contract and development manufacturing organization (CDMO).  The Group offers a distinctive value proposition across the value chain combining diversified high value-added dosage forms manufacturing (liquid forms, sterile forms, multi-doses, freeze-drying, solid forms, etc.) with top-notch development services. Synerlab operates 6 complementary and specialized facilities adapted to both small/medium and large series in France and in Spain including 1 site dedicated to outsourced development activities. The Group employs 1,300 people, including a thousand in France and nearly 300 in Spain. The transaction follows Blue Wolf Capital's acquisition of 7 European sites from Recipharm in 2024, primarily located in Northern Europe, with the objective of building a European industry-leading CDMO platform.